Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes? | Zendy

Daniele Focosi | Zendy; Marco Tuccori | Zendy; Fabrizio Maggi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?

Author(s) -

Daniele Focosi,

Marco Tuccori,

Fabrizio Maggi

Publication year - 2019

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2019.11.07

Subject(s) - progressive multifocal leukoencephalopathy , natalizumab , medicine , rituximab , jc virus , leukoencephalopathy , multiple sclerosis , fingolimod , immunology , virology , antibody , pathology , disease

Progressive multifocal leukoencephalopathy (PML) has evolved in the last decade from a disorder of acquired immune deficiency syndrome (AIDS) patients into a rare but fatal complication of several life-saving therapeutics (ranging from rituximab in non-Hodgkin lymphomas to natalizumab in multiple sclerosis). PML is linked to opportunistic reactivation of the latent human JC polyomavirus (JCV), which leads to emergence of neurotropic strains causing brain demyelination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research